We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$395M
Cap. Flow %
-10.28%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17
Avg Time Held Equity + Options
4.9 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.8 quarters
Avg Time Held Equity only
5.3 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
7.4 quarters

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD icon
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW icon
WW International
WW
+$487M
2
BPMC icon
Blueprint Medicines
BPMC
+$13.9M
3
ONC icon
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 46.31%
2 Consumer Discretionary 28.3%
3 Miscellaneous 25.15%
4 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TRIL
101
DELISTED
Trillium Therapeutics Inc.
TRIL
$870K 0.02%
150,000
– –
2017 Q4
3 quarters
UBX icon
102
DELISTED
Unity Biotechnology
UBX
$815K 0.02%
5,000
-15,000
-75% -$2.47M
2018 Q2
1 quarter
NVLN
103
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$759K 0.02%
256,400
– –
2016 Q4
7 quarters
ATYR icon
104
aTyr Pharma
ATYR
$24.1M
$406K 0.01%
35,714
– –
2017 Q3
4 quarters
IMDX icon
105
Insight Molecular Diagnostics
IMDX
$110M
$375K 0.01%
7,500
– –
2016 Q1
10 quarters
AGIO icon
106
CALL
Agios Pharmaceuticals
AGIO
$1.9B
– –
-50,000
Closed -$4.21M –
BLUE icon
107
CALL
DELISTED
bluebird bio
BLUE
– –
-3,860
Closed -$7.85M –
BPMC icon
108
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-200,000
Closed -$12.7M –
DVAX icon
109
CALL
DELISTED
Dynavax Technologies
DVAX
– –
-250,000
Closed -$3.81M –
EXEL icon
110
CALL
Exelixis
EXEL
$14.8B
– –
-500,000
Closed -$10.8M –
FBRX icon
111
DELISTED
Forte Biosciences
FBRX
– –
-267
Closed -$934K –
CBIO icon
112
Crescent Biopharma
CBIO
$554M
– –
-2,500
Closed -$4.03M –
IBB icon
113
CALL
iShares Biotechnology ETF
IBB
$10.6B
– –
-450,000
Closed -$49.4M –
IMUX icon
114
Immunic
IMUX
$112M
– –
-2,500
Closed -$6.85M –
KNSA icon
115
Kiniksa Pharmaceuticals
KNSA
$6.22B
– –
-100,000
Closed -$1.74M –
SNDX icon
116
Syndax Pharmaceuticals
SNDX
$1.52B
– –
-60,697
Closed -$426K –
WVE icon
117
Wave Life Sciences
WVE
$682M
– –
-100,000
Closed -$3.83M –
ACGN
118
DELISTED
Aceragen Inc
ACGN
– –
-20,241
Closed -$3.63M –
CLVS
119
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-100,000
Closed -$4.55M –
GBT
120
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-200,000
Closed -$9.04M –
XLRN
121
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-100,000
Closed -$4.85M –
SNNA
122
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
– –
-99,000
Closed -$1.5M –
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $395M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.